BACKGROUND: The Centers for Disease Control and Prevention (CDC) and others reported that methicillin-resistant S. aureus (MRSA) are significant causes of serious human infections, including pulmonary illnesses. We investigated the role played by superantigens in lung-associated lethal illness in rabbits. METHODS: A rabbit model was established to investigate the potential role played by superantigens, staphylococcal enterotoxin B (SEB), staphylococcal enterotoxin C (SEC), and toxic shock syndrome toxin-1 (TSST-1). Rabbits received intrabronchial community-associated (CA) MRSA strains USA200 (TSST-1(+)), MW2 (SEC(+)), c99-529 (SEB(+)), or purified superantigens. Some rabbits were preimmunized against superantigens or treated with soluble high-affinity T cell receptors (Vβ-TCR) to neutralize SEB and then challenged intrabronchially with CA-MRSA or superantigens. RESULTS: Rabbits challenged with CA-MRSA or superantigens developed fatal, pulmonary illnesses. Animals preimmunized against purified superantigens, or treated passively with Vβ-TCRs and then challenged with CA-MRSA or superantigens, survived. Lung histological analysis indicated that nonimmune animals developed lesions consistent with necrotizing pneumonia after challenge with CA-MRSA or purified superantigens. Superantigen-immune animals or animals treated with soluble Vβ-TCRs did not develop pulmonary lesions. CONCLUSIONS: Superantigens contribute to lethal pulmonary illnesses due to CA-MRSA; preexisting immunity to superantigens prevents lethality. Administration of high-affinity Vβ-TCR with specificity for SEB to nonimmune animals protects from lethal pulmonary illness resulting from SEB(+) CA-MRSA and SEB.
BACKGROUND: The Centers for Disease Control and Prevention (CDC) and others reported that methicillin-resistant S. aureus (MRSA) are significant causes of serious humaninfections, including pulmonary illnesses. We investigated the role played by superantigens in lung-associated lethal illness in rabbits. METHODS: A rabbit model was established to investigate the potential role played by superantigens, staphylococcal enterotoxin B (SEB), staphylococcal enterotoxin C (SEC), and toxic shock syndrometoxin-1 (TSST-1). Rabbits received intrabronchial community-associated (CA) MRSA strains USA200 (TSST-1(+)), MW2 (SEC(+)), c99-529 (SEB(+)), or purified superantigens. Some rabbits were preimmunized against superantigens or treated with soluble high-affinity T cell receptors (Vβ-TCR) to neutralize SEB and then challenged intrabronchially with CA-MRSA or superantigens. RESULTS:Rabbits challenged with CA-MRSA or superantigens developed fatal, pulmonary illnesses. Animals preimmunized against purified superantigens, or treated passively with Vβ-TCRs and then challenged with CA-MRSA or superantigens, survived. Lung histological analysis indicated that nonimmune animals developed lesions consistent with necrotizing pneumonia after challenge with CA-MRSA or purified superantigens. Superantigen-immune animals or animals treated with soluble Vβ-TCRs did not develop pulmonary lesions. CONCLUSIONS: Superantigens contribute to lethal pulmonary illnesses due to CA-MRSA; preexisting immunity to superantigens prevents lethality. Administration of high-affinity Vβ-TCR with specificity for SEB to nonimmune animals protects from lethal pulmonary illness resulting from SEB(+) CA-MRSA and SEB.
Authors: Maria Labandeira-Rey; Florence Couzon; Sandrine Boisset; Eric L Brown; Michele Bes; Yvonne Benito; Elena M Barbu; Vanessa Vazquez; Magnus Höök; Jerome Etienne; François Vandenesch; M Gabriela Bowden Journal: Science Date: 2007-01-18 Impact factor: 47.728
Authors: Patrick M Schlievert; Laura C Case; Kimberly A Nemeth; Catherine C Davis; Yiping Sun; Wendy Qin; Fancheng Wang; Amanda J Brosnahan; John A Mleziva; Marnie L Peterson; Bruce E Jones Journal: Biochemistry Date: 2007-11-20 Impact factor: 3.162
Authors: R Monina Klevens; Melissa A Morrison; Joelle Nadle; Susan Petit; Ken Gershman; Susan Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; Allen S Craig; Elizabeth R Zell; Gregory E Fosheim; Linda K McDougal; Roberta B Carey; Scott K Fridkin Journal: JAMA Date: 2007-10-17 Impact factor: 56.272
Authors: Patrick M Schlievert; Kristi L Strandberg; Ying-Chi Lin; Marnie L Peterson; Donald Y M Leung Journal: J Allergy Clin Immunol Date: 2010-01 Impact factor: 10.793
Authors: Adam R Spaulding; Wilmara Salgado-Pabón; Joseph A Merriman; Christopher S Stach; Yinduo Ji; Aaron N Gillman; Marnie L Peterson; Patrick M Schlievert Journal: J Infect Dis Date: 2013-12-19 Impact factor: 5.226
Authors: D M Mattis; A R Spaulding; O N Chuang-Smith; E J Sundberg; P M Schlievert; D M Kranz Journal: Protein Eng Des Sel Date: 2012-11-15 Impact factor: 1.650
Authors: Julia Svedova; Antoine Ménoret; Payal Mittal; Joseph M Ryan; James A Buturla; Anthony T Vella Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-05-04 Impact factor: 5.464
Authors: Avanish K Varshney; Xiaobo Wang; Jennifer MacIntyre; Richard S Zollner; Kerry Kelleher; Oleg V Kovalenko; Ximo Pechuan; Fergus R Byrne; Bettina C Fries Journal: J Infect Dis Date: 2014-05-05 Impact factor: 5.226